Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 61Recurrence 10Lymphoma 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia 1Kidney Failure, Chronic 1

Interventions

Everolimus 5Topotecan 2Etoposide 2Cisplatin 2Bevacizumab 2veliparib 1pralsetinib 1pertuzumab 1pembrolizumab 1pasireotide 1lenvatinib 1carfilzomib 1cabozantinib 1berzosertib 1Temozolomide 1Sunitinib 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Podophyllotoxin 1Platinum 1Octreotide 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Neuroendocrine × carfilzomib × Clear all
NCT02318784 2023-12-05

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
62 enrolled 10 charts
Endocrine

Carcinoid Tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡